CM Life Sciences in an 8-K filing said shareholders voted in favor of the merger with Sema4, an AI- and machine learning-driven patient-centered genomic and clinical data intelligence company. Sema4 today announced the closing of the deal.
The transaction values Sema4 at an enterprise value of approximately $2 billion.
The filing did not mention redemptions, if any, although the vote was overwhelmingly in favor of the acquisition.
Announced in February, the deal is expected to provide aproximately $500 million in cash proceeds to shareholders and Sema4.
Proceeds include a fully committed PIPE of $350 million from growth and life science investors including Casdin Capital, Corvex Management, Fidelity Management & Research Company, Counterpoint Global (Morgan Stanley), Perceptive Advisors, SB Management, a subsidiary of SoftBank Group Corp, funds and accounts advised by T. Rowe Price Associates Inc and Viking Global Investors, and existing investors including fund and accounts managed by Blackrock and Deerfield Management. Read more.
